By Dr Rachel Lagiakos (Schrödinger)2024-05-31T09:27:36
Dr H. Rachel Lagiakos is a Senior Principal Scientist in the Therapeutics Group at Schrödinger which she joined in 2018. She completed her PhD in Synthetic Organic Chemistry at Monash University and began her medicinal chemistry career at Cancer Therapeutics (CTx) in Melbourne, Australia in 2012. At CTx, Rachel’s contributions ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-11T14:00:00
Sponsored by Merck
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2026-06-02T15:00:00 2026-06-02T16:00:00
Sponsored by Danaher Life Sciences
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud